The Cancer Biomarker Market is expected to record a CAGR of nearly 13% over the forecast period. Certain factors driving the market growth include increased cancer incidence worldwide, increased acceptance of cancer treatment in developing countries, medical paradigm shift from disease diagnosis to risk assessment or early diagnosis, and increased use of biomarkers in drug development.
A full report of Cancer Biomarkers Market available at https://www.orionmarketreports.com/cancer-biomarker-market/11654/
Cancer Biomarkers Market: Segmentation
By Profiling Technology
• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics-based Tests
By Biomolecule
• Genetic Biomarkers
• Protein Biomarkers
• Glyco-biomarkers
By Cancer Type
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Others
By Application
• Diagnostics
• Drug Discovery and Development
• Prognostics
• Risk Assessment
• Others
Market Key Players
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• QIAGEN
• bioMérieux, Inc.
• Creative Diagnostics
• Hologic Inc.
• Quest Diagnostics
• Myriad Genetics, Inc.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
